How much can elacestrant shrink tumors?

Elacestrant has demonstrated significant tumor shrinkage in clinical trials, particularly in patients with ER+ and HER2- advanced or metastatic breast cancer with ESR1 mutations. As a selective estrogen receptor degrader (SERD), elastran inhibits the growth stimulation of breast cancer cells by estrogen by promoting the degradation of estrogen receptors, thereby achieving the effect of shrinking tumors.

In key clinical studies, elastran has shown more significant efficacy than traditional endocrine therapy drugs (such as tamoxifen, anastrozole, etc.). Especially in patients with ESR1 mutations, the effect of elastran is particularly prominent. This mutation often leads to breast cancer resistance to traditional endocrine therapy, and elastran can effectively overcome this resistance.

According to the results of clinical trials, treatment with elastran can significantly delay tumor progression and improve progression-free survival (PFS). Some research data show that compared with placebo, elastran can significantly improve the tumor shrinkage rate of patients. Some patients' tumors have significantly shrunk, and in individual cases, the tumor volume has even been reduced by more than 50%. These data demonstrate that elastran can not only effectively control the progression of breast cancer, but also achieve significant tumor shrinkage in some patients, providing significant clinical benefit.

The tumor shrinking effect of elastran is usually manifested by a reduction in tumor size, especially in patients who have received multiple endocrine therapies. This drug reduces the dependence of cancer cells on estrogen by efficiently degrading estrogen receptors, thereby inhibiting further tumor growth. For some patients with strong drug resistance, elastran provides an effective treatment option that can reduce tumor size and improve patient survival.

References:https://www.drugs.com/mtm/elacestrant.html